We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Delays Sanofi Diabetes Drug, Leaving Door Open for Competitor
FDA Delays Sanofi Diabetes Drug, Leaving Door Open for Competitor
The FDA has asked for more information on the pen injector device used in Sanofi and Zealand Pharma's IGlarLixi combination product for diabetes, and extended its review by three months, hurting its chances to be the first product of its kind on the U.S. market.